CN116615431A - 硼酸类化合物 - Google Patents

硼酸类化合物 Download PDF

Info

Publication number
CN116615431A
CN116615431A CN202180055494.1A CN202180055494A CN116615431A CN 116615431 A CN116615431 A CN 116615431A CN 202180055494 A CN202180055494 A CN 202180055494A CN 116615431 A CN116615431 A CN 116615431A
Authority
CN
China
Prior art keywords
compound
stirred
mixture
ethyl acetate
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180055494.1A
Other languages
English (en)
Chinese (zh)
Inventor
秦东辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Huinuo Biomedical Technology Hangzhou Co ltd
Original Assignee
Huinuo Biomedical Technology Hangzhou Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Huinuo Biomedical Technology Hangzhou Co ltd filed Critical Huinuo Biomedical Technology Hangzhou Co ltd
Publication of CN116615431A publication Critical patent/CN116615431A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180055494.1A 2020-08-20 2021-08-20 硼酸类化合物 Pending CN116615431A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN2020108450011 2020-08-20
CN202010845001 2020-08-20
CN202110373982 2021-04-07
CN2021103739829 2021-04-07
PCT/CN2021/113815 WO2022037680A1 (zh) 2020-08-20 2021-08-20 硼酸类化合物

Publications (1)

Publication Number Publication Date
CN116615431A true CN116615431A (zh) 2023-08-18

Family

ID=80322587

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180055494.1A Pending CN116615431A (zh) 2020-08-20 2021-08-20 硼酸类化合物

Country Status (7)

Country Link
US (1) US12590108B2 (https=)
EP (1) EP4201942A4 (https=)
JP (1) JP2023538645A (https=)
KR (1) KR20230104117A (https=)
CN (1) CN116615431A (https=)
TW (1) TW202214261A (https=)
WO (1) WO2022037680A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023155869A1 (zh) * 2022-02-18 2023-08-24 辉诺生物医药科技（杭州）有限公司 新的硼酸类化合物的晶型及其制备方法
WO2025228222A1 (zh) * 2024-04-30 2025-11-06 珠海联邦制药股份有限公司 硼酸类β-内酰胺酶抑制剂及其应用
WO2026067428A1 (zh) * 2024-09-30 2026-04-02 科睿迪(南京)医药科技有限公司 硼酸衍生物及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010056827A1 (en) * 2008-11-13 2010-05-20 Protez Pharmaceuticals, Inc. Beta-lactamase inhibitors
US20100292185A1 (en) * 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
CN105026407A (zh) * 2012-12-07 2015-11-04 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
US20180051041A1 (en) * 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CN109415386A (zh) * 2016-06-30 2019-03-01 Qpex生物制药有限公司 硼酸衍生物及其治疗用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012491B2 (en) * 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010056827A1 (en) * 2008-11-13 2010-05-20 Protez Pharmaceuticals, Inc. Beta-lactamase inhibitors
US20100292185A1 (en) * 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
CN105026407A (zh) * 2012-12-07 2015-11-04 维纳拓尔斯制药公司 β-内酰胺酶抑制剂
US20180051041A1 (en) * 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US20190211037A1 (en) * 2015-03-17 2019-07-11 Qpex Biopharma, Inc. Boronic acid derivatives and their therapeutic uses in antimicrobial treatment
CN109415386A (zh) * 2016-06-30 2019-03-01 Qpex生物制药有限公司 硼酸衍生物及其治疗用途

Also Published As

Publication number Publication date
WO2022037680A1 (zh) 2022-02-24
TW202214261A (zh) 2022-04-16
US12590108B2 (en) 2026-03-31
KR20230104117A (ko) 2023-07-07
US20240294554A1 (en) 2024-09-05
EP4201942A1 (en) 2023-06-28
JP2023538645A (ja) 2023-09-08
EP4201942A4 (en) 2024-08-21

Similar Documents

Publication Publication Date Title
WO2022222995A1 (zh) 吡啶酰胺类化合物
WO2021052499A1 (zh) 稠合吡啶酮类化合物及其制备方法和应用
CN114174282A (zh) 作为甲状腺素受体-β激动剂的哒嗪酮类衍生物及其应用
TWI781342B (zh) KEAP1-Nrf2蛋白-蛋白交互作用抑制劑
WO2020200316A1 (zh) 作为ret抑制剂的吡唑并吡啶类化合物及其应用
CN104918935B (zh) 二氢吡唑gpr40调节剂
CN116615431A (zh) 硼酸类化合物
WO2025040170A1 (zh) 作为CDKs抑制剂的新型并杂环类新化合物及其应用
TW202128699A (zh) 治療性化合物
WO2022166721A1 (zh) 含1，4-氧杂氮杂环庚烷的并环类衍生物
WO2022262782A1 (zh) 戊二酰亚胺取代的异噁唑稠环化合物及其应用
WO2022247757A1 (zh) 氟取代的嘧啶并吡啶类化合物及其应用
WO2023001069A1 (zh) 大环酰胺类化合物及其应用
TW202523662A (zh) 雜環glp-1受體激動劑及其應用
WO2023241618A1 (zh) 氨基嘧啶类化合物及其应用
WO2023284651A1 (zh) N-(2-氨基苯基)苯甲酰胺类化合物及其应用
WO2022063308A1 (zh) 一类1,7-萘啶类化合物及其应用
KR20230164702A (ko) 이중 고리계 화합물의 제조 방법 및 항균제로서의 용도
WO2023208127A1 (zh) 杂芳基取代的双环化合物及其应用
KR102500569B1 (ko) 선택적 btk 키나제 억제제로서의 피라졸로피리딘계 화합물
CN111315750B (zh) 作为mTORC1/2双激酶抑制剂的吡啶并嘧啶类化合物
TW202128703A (zh) 作為m4 促效劑之2-氮雜螺[3.4]辛烷衍生物
TWI814092B (zh) 稠合的三并環衍生物及其在藥學上的應用
WO2022199635A1 (zh) 苄氨基喹唑啉类衍生物
WO2022053028A1 (zh) 1,2,4-三嗪-3,5(2h,4h)-二酮类化合物及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40099197

Country of ref document: HK